Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
The inspection closed with the facility receiving an inspection classification of NAI
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
The inspection closed with zero observations
The company will submit its comprehensive response on these observations to the US FDA
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Subscribe To Our Newsletter & Stay Updated
